癌症诊断与缺血性及出血性卒中、心肌梗死后死亡风险的关联
基于台湾全国联动数据库的人群队列研究,纳入2011至2019年间首次缺血性卒中、出血性卒中及心肌梗死患者,通过倾向评分匹配分析癌症诊断与90天死亡率的关系。结果显示,癌症患者在上述三种事件后的90天死亡风险均显著升高,且不同癌症类型差异明显,诊断后第一年超额死亡率最高。
要点
- 癌症患者缺血性卒中后90天死亡风险为匹配对照的2.71倍。
- 出血性卒中和心肌梗死后的相应风险分别为2.20倍和1.63倍。
- 侵袭性恶性肿瘤(如胰腺癌)风险最高,诊断后第一年超额死亡率最大。
核心结论
- 癌症诊断与卒中及心肌梗死后90天死亡风险升高相关,且因癌症类型而异。
研究设计与样本
- 基于台湾全国联动数据库的人群为基础队列研究,纳入2011至2019年首次缺血性卒中(440664例)、出血性卒中(159606例)和心肌梗死(228993例)患者。
主要发现
- 癌症患者缺血性卒中后90天死亡OR为2.71(95%CI 2.63-2.79),出血性卒中为2.20(95%CI 2.11-2.29),心肌梗死为1.63(95%CI 1.57-1.69)。
- 超额死亡率在癌症诊断后第一年最高,随后逐渐下降,该模式在各年龄组和癌症分期中一致。
- 18-59岁患者及IV期癌症患者的超额死亡率最高,尽管癌症类型间存在差异,超额死亡率通常在2年内达峰。
临床怎么用
- 对合并癌症的卒中或心肌梗死患者,应认识到其短期死亡风险显著增高,尤其侵袭性癌症及诊断后第一年。
- 年轻癌症患者和晚期癌症患者事件后死亡风险更高,需加强监测与支持治疗。
局限性
- 缺乏死因别死亡率数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Previous studies have indicated an increased risk of cerebrovascular and coronary events shortly after cancer diagnosis. However, whether cancer affects mortality outcomes after stroke and myocardial infarction (MI) remains unclear. We aimed to investigate the relationship between cancer diagnosis and mortality after stroke and MI. METHODS: Using linked nationwide databases from Taiwan, we conducted a population-based cohort study including 3 cohorts of patients with first-time ischemic stroke, hemorrhagic stroke, and MI between 2011 and 2019. The primary outcome was 90-day mortality, with follow-up beginning at the index stroke (for ischemic and hemorrhagic stroke cohorts) and MI (for the MI cohort) event date for all patients. Odds ratios (ORs) of 90-day mortality associated with all cancers combined and 15 cancer types were estimated through propensity score matching for potential confounding variables. Excess mortality rates (between patients with cancer and matched controls) were analyzed across time intervals after cancer diagnosis, stratified by age group, cancer stage, and cancer type. RESULTS: Overall, 440,664, 159,606, and 228,993 patients were included in ischemic stroke (mean age, 70.1 years; 40.7% female), hemorrhagic stroke (mean age, 65.4 years; 36.5% female), and MI (mean age, 67.8 years; 29.7% female) cohorts, respectively. Compared with matched controls, patients with cancer had higher risks of 90-day mortality in ischemic stroke (OR 2.71, 95% CI 2.63-2.79), hemorrhagic stroke (OR 2.20, 95% CI 2.11-2.29), and MI (OR 1.63, 95% CI 1.57-1.69). Across 3 cohorts, substantial variations existed among cancer types, with aggressive malignancies (e.g., pancreatic cancer) consistently presenting the highest risks. Excess mortality rates were highest during the first postdiagnosis year and declined progressively thereafter. This temporal pattern was consistent across age groups and cancer stages, with excess mortality rates highest among patients aged 18-59 years and those with stage 4 disease. Despite variability among cancer types, excess mortality typically peaked within 2 years. DISCUSSION: This population-based study showed that patients with cancer had higher risks of mortality after stroke and MI, with substantial variations by cancer type, although cause-specific mortality data were lacking. Excess mortality rates peaked shortly after diagnosis, particularly for early-onset cancer and advanced disease.
引用
- Huang YT, Cheng MC, Hsieh CY, et al. Association of a Cancer Diagnosis and Mortality After Ischemic and Hemorrhagic Stroke and Myocardial Infarction. Neurology. 2026. PMID: 41637680. doi:10.1212/WNL.0000000000214649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。